Gilead Sciences, Inc. $GILD Shares Bought by Brucke Financial Inc.

Brucke Financial Inc. raised its holdings in Gilead Sciences, Inc. (NASDAQ:GILD) by 57.8% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 3,611 shares of the biopharmaceutical company’s stock after purchasing an additional 1,322 shares during the period. Brucke Financial Inc.’s holdings in Gilead Sciences were worth $400,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. One Wealth Advisors LLC raised its position in shares of Gilead Sciences by 34.8% during the 2nd quarter. One Wealth Advisors LLC now owns 9,163 shares of the biopharmaceutical company’s stock valued at $1,016,000 after acquiring an additional 2,364 shares in the last quarter. Ariel Investments LLC raised its position in shares of Gilead Sciences by 7.7% during the 1st quarter. Ariel Investments LLC now owns 430,424 shares of the biopharmaceutical company’s stock valued at $48,229,000 after acquiring an additional 30,630 shares in the last quarter. Golden State Wealth Management LLC raised its position in shares of Gilead Sciences by 14.5% during the 1st quarter. Golden State Wealth Management LLC now owns 863 shares of the biopharmaceutical company’s stock valued at $97,000 after acquiring an additional 109 shares in the last quarter. Covea Finance raised its position in shares of Gilead Sciences by 69.5% during the 2nd quarter. Covea Finance now owns 51,700 shares of the biopharmaceutical company’s stock valued at $5,732,000 after acquiring an additional 21,200 shares in the last quarter. Finally, Swedbank AB raised its position in shares of Gilead Sciences by 0.8% during the 1st quarter. Swedbank AB now owns 2,118,632 shares of the biopharmaceutical company’s stock valued at $237,393,000 after acquiring an additional 16,663 shares in the last quarter. 83.67% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CFO Andrew D. Dickinson sold 2,500 shares of the stock in a transaction on Monday, September 15th. The stock was sold at an average price of $113.57, for a total value of $283,925.00. Following the completion of the transaction, the chief financial officer owned 159,555 shares of the company’s stock, valued at approximately $18,120,661.35. This represents a 1.54% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, insider Johanna Mercier sold 28,000 shares of the stock in a transaction on Friday, August 15th. The stock was sold at an average price of $118.53, for a total value of $3,318,840.00. Following the completion of the transaction, the insider directly owned 114,168 shares of the company’s stock, valued at approximately $13,532,333.04. The trade was a 19.70% decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 82,000 shares of company stock worth $9,402,130. 0.27% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on GILD. Dbs Bank raised Gilead Sciences to a “moderate buy” rating in a research report on Friday, September 5th. Truist Financial raised Gilead Sciences from a “hold” rating to a “buy” rating and upped their price target for the company from $108.00 to $127.00 in a research report on Friday, August 8th. UBS Group upped their price objective on Gilead Sciences from $108.00 to $112.00 and gave the stock a “neutral” rating in a research note on Friday, August 8th. Cantor Fitzgerald upped their price objective on Gilead Sciences from $129.00 to $135.00 and gave the stock an “overweight” rating in a research note on Thursday. Finally, Weiss Ratings restated a “buy (b)” rating on shares of Gilead Sciences in a research note on Wednesday. Two research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and six have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $118.08.

Gilead Sciences Price Performance

Shares of GILD opened at $117.18 on Friday. Gilead Sciences, Inc. has a 12 month low of $84.17 and a 12 month high of $121.83. The company has a market cap of $145.40 billion, a P/E ratio of 23.34, a PEG ratio of 0.79 and a beta of 0.34. The stock has a fifty day moving average price of $114.65 and a 200 day moving average price of $110.25. The company has a debt-to-equity ratio of 1.13, a current ratio of 1.32 and a quick ratio of 1.15.

Gilead Sciences (NASDAQ:GILD) last released its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported $2.01 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.96 by $0.05. Gilead Sciences had a return on equity of 50.99% and a net margin of 21.86%.The company had revenue of $7.08 billion during the quarter, compared to analysts’ expectations of $6.95 billion. During the same quarter in the prior year, the business posted $2.01 earnings per share. The company’s revenue for the quarter was up 1.4% compared to the same quarter last year. Gilead Sciences has set its FY 2025 guidance at 7.950-8.250 EPS. On average, research analysts forecast that Gilead Sciences, Inc. will post 7.95 earnings per share for the current year.

Gilead Sciences Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, September 29th. Stockholders of record on Monday, September 15th were paid a $0.79 dividend. The ex-dividend date of this dividend was Monday, September 15th. This represents a $3.16 annualized dividend and a dividend yield of 2.7%. Gilead Sciences’s dividend payout ratio is presently 62.95%.

About Gilead Sciences

Gilead Sciences, Inc, a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis.